ArticleJournal of biochemical and molecular toxicology2026
Fisetin Attenuates Uterine Leiomyoma in Rats: Potential Crosstalk Between HMGB1, SphK1/S1P, and TGF-β Signaling.
Article in Journal of biochemical and molecular toxicology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Uterine leiomyomas (UL) represent one of the most prevalent gynecological benign tumors with a considerable global medical and economic burden. Effective therapeutic strategies that preserve the uterus and maintain fertility are still lacking. Fisetin (FIS), a naturally occurring dietary flavonoid, exhibits antitumor, anti-inflammatory, and antifibrotic properties, yet its therapeutic potential in UL remains incompletely defined. This study investigated the therapeutic effects of fisetin on UL and the possible underlying mechanisms. UL was experimentally induced in adult female rats by monosodium glutamate (MSG), and animals were assigned to Control, FIS, UL, and UL + FIS groups. Blood and tissue samples were subjected to hormonal, biochemical, histopathological, and immunohistochemical assessments. Serum estradiol, progesterone, and S1P levels were measured using ELISA, while qPCR quantified the expression of key signaling molecules, including SphK1, TGF-β1, HMGB1, TNF-α, and IL-1β. Immunohistochemistry assessed TGF-β1 and α-SMA expressions, and histopathology (H&E and Masson's Trichrome stains) evaluated tissue architecture and fibrosis. The results showed that fisetin administration significantly reduced the elevated sex hormones, inhibited S1P signaling, and suppressed proinflammatory mediators (HMGB1, TNF-α, IL-1β) and profibrotic mediators (TGF-β1, α-SMA). Histopathological evaluation confirmed decreased fibrotic remodeling and improved tissue architecture. Overall, these results suggest that fisetin's effect may involve coordinated modulation of the S1P/SphK1, TGF-β, and HMGB1 axes, highlighting its potential as a novel uterus-preserving therapeutic agent for UL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.